The incidence of silent cerebral embolisms (SCEs) has been documented after pulmonary vein isolation using different ablation technologies; however, it is unreported in patients undergoing with atrial fibrillation (AF) ablation using Robotic Magnetic Navigation (RMN). The purpose of this prospective study was to investigate the incidence, risk predictors and probable mechanisms of SCEs in patients with AF ablation and the potential impact of RMN on SCE rates. We performed a prospective study of 166 patients with paroxysmal or persistent AF who underwent pulmonary vein isolation. Patients were divided into RMN group ( = 104) and manual control (MC) group ( = 62), and analyzed for their demographic, medical, echocardiographic, and risk predictors of SCEs. All patients underwent cerebral magnetic resonance imaging within 48 h before and after the ablation procedure to assess cerebral embolism. The incidence and potential risk factors of SCEs were compared between the two groups. There were 26 total cases of SCEs in this study, including 6 cases in the RMN group and 20 cases in the MC group. The incidences of SCEs in the RMN group and the MC group were 5.77 and 32.26%, respectively (X = 20.63 < 0.05). Univariate logistic regression analysis demonstrated that ablation technology, CHADS-VASc score, history of cerebrovascular accident/transient ischemic attack, and low ejection fraction were significantly associated with SCEs, and multivariate logistic regression analysis showed that MC ablation was the only independent risk factor of SCEs after an AF ablation procedure. Ablation technology, CHADS-VASc score, history of cerebrovascular accident/transient ischemic attack, and low ejection fraction are associated with SCEs. However, ablation technology is the only independent risk factor of SCEs and RMN can significantly reduce the incidence of SCEs resulting from AF ablation. ChiCTR2100046505.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671737 | PMC |
| http://dx.doi.org/10.3389/fcvm.2021.777355 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bone quality analysis of the mandible in alcoholic liver cirrhosis: Anatomical, microstructural, and microhardness evaluation.
Bone
December 2024
Center of Bone Biology, Institute for Anatomy, Faculty of Medicine, Dr Subotica starijeg 4, 11000 Belgrade, Serbia. Electronic address:
Objectives: Alcoholic bone disease has been recognized in contemporary literature as a systemic effect of chronic ethanol consumption. However, evidence about the specific influence of alcoholic liver cirrhosis (ALC) on mandible bone quality is scarce. The aim of this study was to explore microstructural, compositional, cellular, and mechanical properties of the mandible in ALC individuals compared with a healthy control group.
View Article and Find Full Text PDFB-Site-Ordered and Disordered Structures in A-Site-Ordered Quadruple Perovskites RMnNiMnO with R = Nd, Sm, Gd, and Dy.
Molecules
November 2024
Research Center for Materials Nanoarchitectonics (MANA), National Institute for Materials Science (NIMS), Namiki 1-1, Tsukuba 305-0044, Ibaraki, Japan.
ABO perovskite materials with small cations at the A site, especially with ordered cation arrangements, have attracted a lot of interest because they show unusual physical properties and deviations from general perovskite tendencies. In this work, A-site-ordered quadruple perovskites, RMnNiMnO with R = Nd, Sm, Gd, and Dy, were synthesized by a high-pressure, high-temperature method at about 6 GPa. Annealing at about 1500 K produced samples with additional (partial) B-site ordering of Ni and Mn cations, crystallizing in space group -3.
View Article and Find Full Text PDFTwice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
N Engl J Med
November 2024
From the Hope Clinic of the Emory University School of Medicine, Decatur (C.F.K.), and Grady Health System (C.F.K.), and the Division of Infectious Diseases, Emory University-Ponce de Leon Center Clinical Research Site, HIV/AIDS Clinical Trials Unit (V.D.C.), Atlanta - all in Georgia; the Divisions of Pediatric and Adult Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore (A.L.A.); Be Well Medical Center, Berkley, MI (P.B.); the Department of Medicine, University of California, San Diego, San Diego (J.B.), the Department of Medicine, University of California, Los Angeles (J.C.), Ruane Clinical Research (P.J.R.), and Drew Center for AIDS Research, Education, and Services, Charles R. Drew University (L.Y.S.), Los Angeles, Optimus Medical Group/StudyOps, San Francisco (S.H.), Mills Clinical Research, West Hollywood (A.M.), Bios Clinical Research, Palm Springs (P.S.), and Gilead Sciences, Foster City (S.C., R.E., P.W., R.S., L.B.B., C.C.C., M.D., J.M.B.) - all in California; Central Texas Clinical Research, Austin (C. Brinson), and Crofoot MD Clinic and Research Center, Houston (G.C.) - both in Texas; the Department of Infectious Diseases, Louisiana State University Health Sciences Center-New Orleans, New Orleans (M.C.); Howard Brown Health (C.C.) and the Division of Infectious Diseases, University of Illinois Health Sciences (R.M.N.) - both in Chicago; the Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami (S.D.-L.), Therafirst Medical Center, Fort Lauderdale (A.L.), Midway Immunology and Research Center, Fort Pierce (M.R.), and CAN Community Health, Sarasota (T.S.) - all in Florida; the Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN (A.G.); Washington Health Institute, Washington, DC (T.H.); Fenway Health Medical Clinic, Boston (K.H.M.); Philadelphia FIGHT Community Health Centers-Jonathan Lax Treatment Center, Philadelphia (K.M.); the Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham (O.T.V.G.); the Section of Infectious Diseases, Yale School of Medicine, New Haven, CT (O.O.); Centro Ararat, San Juan, Puerto Rico (M.A.-Q.); the HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University (A.A.), and the Institute of HIV Research and Innovation-Pribta Tangerine Clinic (N.P.) - both in Bangkok; Complexo Hospitalar Universitário Professor Edgard Santos, Salvador (C. Brites), Universidade Federal de São Paulo (R.S.D.), Centro de Referência e Treinamento DST/AIDS-SP (J.V.M.), and Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (R.V.), São Paulo, Fundação Oswaldo Cruz-Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro (B.G.), Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus (M.L.), and the Infectious Diseases Service, Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Fundación Huésped (P.C.) and Hospital General de Agudos José María Ramos Mejía (M.H.L.) - both in Buenos Aires; Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos (J.A.G.-C., J.S.) and Via Libre (J.G.V.), Lima, and Asociación Civil Selva Amazónica, Iquitos (J.C.H.) - all in Peru; Desmond Tutu Health Foundation, Cape Town (R.K.), Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg (N.N.), and the Aurum Institute-Pretoria Clinical Research Site, Pretoria (Z.Z.) - all in South Africa; Centro de Investigacion Farmaceutica Especializada de Occidente, Guadalajara, Mexico (A.P.R.); and Gilead Sciences, Cambridge, United Kingdom (C.D.).
Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbinary persons is unclear.
Methods: In this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants in a 2:1 ratio to receive subcutaneous lenacapavir every 26 weeks or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF).
Navigating the Airway Maze: Challenges and Strategies in Deep Neck Space Infections.
Cureus
October 2024
Otolaryngology - Head and Neck Surgery, Kauvery Medical Care (KMC) Speciality Hospitals (I) Ltd., Trichy, IND.
Article Synopsis
- The study investigates the clinical profiles and outcomes of patients diagnosed with deep neck space infections (DNSI), emphasizing the need for early surgical intervention and effective airway management.
- It highlights the primary causes of DNSI, which include nodal and odontogenic origins, and stresses that untreated underlying issues could lead to recurrent infections, increasing risks of morbidity and mortality.
- The research evaluated 20 patients in India, finding that the majority were male, with diabetes being a common risk factor; most cases were of nodal origin, with significant involvement of the submandibular space and the Streptococcus species identified as a common pathogen.
Potential of Marine Sponge Metabolites against Prions: Bromotyrosine Derivatives, a Family of Interest.
Mar Drugs
October 2024
Univ Brest, Inserm, EFS, UMR 1078, GGB, School of Medicine, F-29200 Brest, France.
The screening of 166 extracts from tropical marine organisms (invertebrates, macroalgae) and 3 cyclolipopeptides from microorganisms against yeast prions highlighted the potential of Verongiida sponges to prevent the propagation of prions. We isolated the known compounds purealidin Q (), aplysamine-2 (), pseudoceratinine A (), aerophobin-2 (), aplysamine-1 (), and pseudoceratinine B () for the first time from the Wallisian sponge . We then tested compounds - and sixteen other bromotyrosine and bromophenol derivatives previously isolated from Verongiida sponges against yeast prions, demonstrating the potential of -, , , aplyzanzine C (), purealidin A (), psammaplysenes D () and F (), anomoian F (), and N,N-dimethyldibromotyramine ().
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!